GEC 255
Alternative Names: GEC-255Latest Information Update: 28 Dec 2024
At a glance
- Originator GenEros BioPharma
- Class Antineoplastics
- Mechanism of Action KRAS protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-small cell lung cancer
- No development reported Solid tumours
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater, Treatment-resistant) in China (PO, Tablet)
- 01 Jun 2023 Efficacy and adverse events data from a phase-I trial in Solid tumours released by GenEros
- 07 Sep 2022 Phase-I clinical trials in Non-small cell lung cancer (Late-stage disease) in China (unspecified route) (GenEros Biopharma pipeline, September 2022)